You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 4, April 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease

Maria-Joao Ribeiro, MD, PhD; Marie Vidailhet, MD; Christian Loc'h, BS; Corinne Dupel, MD; Jean Paul Nguyen, MD; Michel Ponchant, BS; Frédéric Dollé, PhD; Marc Peschanski, MD, PhD; Philippe Hantraye, PhD; Pierre Cesaro, MD, PhD; Yves Samson, MD; Philippe Remy, MD, PhD

Arch Neurol. 2002;59:580-586.

Background  Measuring progression of Parkinson disease (PD) using positron emission tomography may help demonstrate the efficacy of neuroprotective treatments. To date, 18F-dopa has been the gold standard to measure presynaptic dopaminergic function in PD, but this tracer might overestimate the rate of neuronal death in PD because its uptake also depends on dopamine turnover rather than exclusively on the density of dopaminergic terminals in the striatum. The latter might be assessed using newly developed ligands of the membrane dopamine transporter.

Objective  To compare the striatal uptakes of 18F-dopa and 76Br-FE-CBT, a dopamine transporter ligand, in patients with PD.

Patients and Methods  The striatal uptakes of 76Br-FE-CBT and 18F-dopa were compared using positron emission tomography in 10 patients with early PD and 8 with advanced PD. Correlation of uptakes with motor performance was investigated.

Results  The reduction in 76Br-FE-CBT binding to 43% of control values was more severe than the reduction in 18F-dopa uptake (63% of control values) in the putamen of patients with early PD. No significant difference was found between either tracer's uptake in the putamen of patients with advanced PD. Motor performance was highly correlated to 18F-dopa uptake, whereas correlation to 76Br-FE-CBT binding was weak.

Conclusions  Uptake of 18F-dopa may be up-regulated in early PD, suggesting a compensatory increase of dopamine synthesis in surviving dopaminergic terminals. Positron emission tomography dopamine transporter ligands and 18F-dopa give complementary information on the presynaptic status of the nigrostriatal dopaminergic system and might be associated to investigate the efficacy of neuroprotective treatments in PD.


From Commissariat à l'Energie Atomique (CEA), Service Hospitalier Frédéric Joliot, Orsay, France (Drs Ribeiro, Dupel, Dollé, Samson, and Remy and Messrs Loc'h and Ponchant); Service de Neurologie, Hôpital Saint-Antoine, Paris, France (Dr Vidailhet); Institut National de la Santé et de la Recherche Médicale (INSERM) U289, Paris (Dr Vidailhet); Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, Assistance Publique-Hôpitaux de Paris & Université Paris 12, Créteil, France (Drs Nguyen, Peschanski, Cesaro, and Remy); INSERM U421, IM3, Faculté de Médecine, Créteil (Drs Nguyen, Peschanski, and Cesaro); Unité de Recherche Associée CEA–Centre National de la Recherche Scientifique 2210, Orsay (Drs Hantraye and Remy); and Urgences Cérébro-Vasculaires, CHU Pitié-Salpétrière, Paris (Dr Samson)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(4):655-656.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations
Ribeiro et al.
JNM 2009;50:1244-1250.
ABSTRACT | FULL TEXT  

BASAL GANGLIA INVOLVEMENT IN TEMPORAL LOBE EPILEPSY: A FUNCTIONAL AND MORPHOLOGIC STUDY
Goldstein et al.
Neurology 2008;71:1840-1841.
FULL TEXT  

Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT
Leroy et al.
JNM 2007;48:538-546.
ABSTRACT | FULL TEXT  

Involvement of the Basal Ganglia in Refractory Epilepsy: An 18F-Fluoro-L-DOPA PET Study Using 2 Methods of Analysis
Bouilleret et al.
JNM 2005;46:540-547.
ABSTRACT | FULL TEXT  

PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy
Biraben et al.
Neurology 2004;63:73-77.
ABSTRACT | FULL TEXT  

Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease
Kerenyi et al.
Arch Neurol 2003;60:1223-1229.
ABSTRACT | FULL TEXT  

18F-Dopa vs Dopamine Transporter Ligands in Positron Emission Tomographic and Single-Photon Emission Computed Tomographic Scans for Parkinson Disease
Fernandez et al.
Arch Neurol 2002;59:1973-1974.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.